Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages

Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of Singapore approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA).

The approval makes Singapore the first country in Southeast Asia to fully approve the latest COVID-19 vaccine for use in individuals 6 months of age and older. The LP.8.1 sublineage was chosen based on guidance from the US FDA, EMA, and WHO, which stated that LP.8.1 is the preferred sublineage for a monovalent JN.1-lineage-based COVID-19 vaccine for the US beginning in fall 2025.Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages

The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner clinics starting in October 2025. Under Singapore’s comprehensive National Vaccination Programme/NVP, the COVID-19 vaccine remains free of charge for all Singapore Citizens, Permanent Residents, Long-Term Pass Holders, and certain Short-Term Pass holders.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally.

BioNTech (NASDAQ:BNTX) is a biotech company that develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments